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Abstract
Objective: Proof of concept study evaluating CMR as screening tool for chronic thromboembolic pulmonary
hypertension (CTEPH) in patients treated for acute pulmonary embolism (PE).
Materials and methods: Right and left ventricular function of 15 consecutive patients treated for PE and 10
consecutive patients in whom PE was excluded was estimated at baseline by cardiac CT and at 6 months follow-
up by CMR. Additionally, during the follow-up visit, pulmonary artery (PA) hemodynamics were studied by CMR
and the presence of pulmonary hypertension by echocardiography.
Results: CT measured right ventricular ejection fraction (RVEF) was lower in patients with PE compared to patients
without PE at time of diagnosis (median 47%, interquartile range 39-53 vs. 55%, 52-58; p = 0.014). After 6 months
follow up, the RVEF between patients treated for PE and patients without PE were not statistically significant
different (55%, 52-60 versus 54%, 51-57; p = 0.57), as were distensibility index (0.18 ± 0.18 versus 0.25 ± 0.18, p =
0.20), mean velocity (14.1 ± 3.9 cm/s versus 14.0 ± 2.5 cm/s, p = 0.81), peak velocity (86.5 ± 22 cm/s versus 89.6 ±
13 cm/s, p = 0.43) and time to peak PA blood flow velocity (142 ± 49 ms versus 161 ± 29 ms, p = 0.14). One
patient was diagnosed with CTEPH and CMR revealed poor right systolic function, decreased PA distensibility and
flow velocity, and a systolic notch in the PA flow profile consistent with persistent PA obstruction.
Conclusion: In this small series, right ventricular performance and PA flow profiles of patients treated for 6 months
after PE are equivalent to those parameters in normal patients.
Introduction
Acute right ventricular (RV) dysfunction associated with
pulmonary embolism (PE), which can both be evaluated
by multi-detector row CT, is caused by increased ten-
sion in the RV wall and may lead to RV dilatation and
ischemia [1,2]. The natural history of RV recovery after
acute PE is largely unknown. Persistent RV dysfunction
after PE might be a predictor of chronic thromboem-
bolic pulmonary hypertension (CTEPH), a rare but ser-
ious long term clinical complication of PE [3]. Because
the underlying pathophysiological mechanism leading to
CTEPH is not fully established and its clinical presenta-
tion is not specific, the early identification of patients
with CTEPH is very difficult [3]. Consequently, the
majority of CTEPH patients present with more
advanced stage disease.
The reference standard for diagnosing pulmonary
hypertension is right heart catheterization [4]. Currently,
the most widely used non-invasive screening tool for
pulmonary hypertension is echocardiography, although
it has been shown that Doppler echocardiography may
frequently be inaccurate in estimating pulmonary artery
pressure and cardiac output in patients being evaluated
for pulmonary hypertension [5]. Cardiovascular mag-
netic resonance (CMR) is a non-invasive modality for
evaluating pulmonary hypertension by evaluation of left
and right systolic and diastolic function as well as by
quantification of pulmonary artery distensibility and pul-
monary flow dynamics [6-10]. CMR measured pulmon-
ary flow dynamics are altered in acute PE as well as in
pulmonary hypertension, and have been shown to corre-
late closely with invasive assessment of cardiac hemody-
namic function and clinical outcome in patients with
pulmonary hypertension [6-10]. Especially pulmonary
artery distensibility has been suggested to be a sensitive
(sensitivity 83%) and specific (specificity 82%) marker
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cal stages [9,10].
We hypothesized that the pulmonary flow dynamics
would restore to normal after 6 months of treatment
following acute PE and therefore would not be different
from patients without PE, except for those patients who
develop CTEPH who will show decreased distensibility
and flow velocity in the pulmonary artery. Following
this, flow profile analysis of the pulmonary artery in the
clinical follow-up of patients with acute PE might be a
helpful screening tool for CTEPH. Accordingly, we per-
formed a proof of concept study to evaluate pulmonary
artery hemodynamics and distensibility at 6 months fol-
low-up in consecutive patients with PE, and in patients
in whom PE was clinically suspected but ruled out as a
control cohort.
Materials and methods
Patients
Since this was a proof of concept study to evaluate the
restoration of pulmonary artery hemodynamics, we
aimed at studying 15 consecutive patients treated for
and 10 consecutive patients in whom PE was ruled out.
Consecutive, hemodynamically stable in- and outpatients
suspected of acute PE were eligible. All patients under-
went multi-detector row computed tomography
(MDCT) of the chest to establish or rule out acute PE
as described by Huisman et al [11]. The presence of PE
was defined as at least one filling defect in the pulmon-
ary artery tree. Furthermore, in all patients, a separate
image acquisition using retrospective ECG-gated
dynamic cardiac MDCT was performed to assess right
and left ventricular function. All scans were performed
according to a standardized protocol, described pre-
viously by Dogan et al in full detail [2]. Scan parameters
were: tube voltage 120 kV and tube current 200 mA.
The optimal pitch factor and rotation time were auto-
matically established to obtain optimal temporal resolu-
tion. Images for functional analysis were reconstructed
in 20 cardiac phases by using a segmental reconstruc-
tion algorithm. The entire heart from aortic root to car-
diac apex was covered within the reconstructed sections
per cardiac phase point. The reconstructed volumes
were transferred to a dedicated workstation running on
Linux software.
ECG-gated multi-detector computed tomography
(MDCT) has been shown to be a reliable method to
assess ventricular volumes and ejection fraction and can
be combined with computed tomography pulmonary
angiography to establish the diagnosis of PE [2,11-14].
Finally, the severity of the pulmonary obstruction was
measured following the method described by Qanadli
and colleagues [15]. Patients with confirmed PE were
initially treated with therapeutic unfractioned or low-
molecular-weight heparin, followed by vitamin K
antagonists for 6 months [16]. Study participants were
excluded if they had a contraindication for CMR scan-
ning, e.g. pregnancy, aneurysm clip in the brain,
implanted neural stimulator, implanted cardiac pace-
maker or defibrillator, or severe claustrophobia. The
study was approved by an institutional review board and
all participants consented to participation.
Follow-up CMR
After 6 months following initial presentation, CMR exami-
nations were performed using a 1.5T CMR scanner (ACS-
NT15 Intera, Philips Medical Systems, Best, the Nether-
lands). We used a five-element phased-array cardiac coil
placed on the chest for signal reception. First, a stack of
14-18 transverse slices (dependent on the size of the
heart) was achieved during breath-holding at end-expira-
tion and by using a steady-state free-precession sequence
for biventricular volume measurements. We used the fol-
lowing scan parameters: slice thickness 10 mm with no
gap, field-of-view = 450 mm (80% rectangular), scan
matrix = 256 × 195, with reconstructed voxels of 1.37 ×
1.37 × 8.0 mm, flip angle a = 35°, repetition time (TR) 3.2
ms and echo time (TE) 1.6 ms. We utilized gated cardiac
synchronization (30 reconstructed phases per cardiac
cycle, temporal resolution 20-35 ms) and parallel imaging
(Sensitivity encoding SENSE, sense factor 2). Using the
MASS software package, we drew the endocardial con-
tours at end-systole and end-diastole manually.
Second, the main pulmonary artery flow curve was
obtained using velocity-encoded (VE) CMR, planned per-
pendicular to the pulmonary artery. The VE CMR acquisi-
tion was performed during breath-holding, with the
acquisition plane planned perpendicular to the pulmonary
trunk distal to the pulmonary valve. Scan parameters: slice
thickness 8 mm; field-of-view = 300 mm (85% rectangu-
lar), scan matrix = 128 × 108, with reconstructed voxels of
1.17 × 1.17 × 8.0 mm, flip angle a 20°, TR/TE = 9.3 ms/
6.1 ms, two signal averages, VENC = 100 cm/s with echo
planar imaging (EPI) factor 7. Pulmonary artery time-to-
peak-velocity, peak-velocity and mean velocity were
assessed. Pulmonary artery contours were semi-automati-
cally drawn using the FLOW software package (FLOW
software package; Medis, Leiden, The Netherlands).
Distensibility index [(Area max (systole) - Area min (dia-
stole))/(Area min)] was determined from the lumen area
measurements of the pulmonary artery at the moment of
maximal flow and at the moment of the isovolumetric
contraction [7]. Two gated acquisitions were performed to
obtain the maximal and minimal luminal areas, using
steady-state free precession sequences with a field-of-view
of 220 mm, voxel size 1.25 × 1.25 × 6.00 mm, flip angle
50°; TR/TE 3.2/1.2 and a gate width of 34.2 ms. The gate
delay was accordingly set that the middle of the
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or the moment of isovolumetric contraction, respectively.
Also, in order to correct for through-plane motion of the
acquisition plane, the location and angulation of this plane
were manually adjusted on both orthogonal cine views of
the right ventricular outflow tract, specifically on the two
phases of the cardiac cycle nearest to the chosen gate
delays as described by Grotenhuis et al [17].
All contours were drawn by one observer (2 years
experience with CMR) supervised by a radiologist (11
years experience with CMR) who were both blinded for
the patients’ condition.
Echocardiography
To evaluate the presence of pulmonary hypertension in
the study patients, all underwent transthoracic echocar-
diography after the CMR was performed. Echocardiogra-
phy included cross sectional, M-mode and Doppler
studies, and was performed by an experienced techni-
cian according to a standardized protocol. In case of
suspected pulmonary hypertension (1) maximal tricuspid
regurgitation velocity >2.8 m/s, 2) estimated systolic pul-
monary artery pressure ≥35 mmHg, 3) estimated mean
pulmonary artery pressure ≥25 mmHg 4) borderline
value of criterion 1 or 2 in combination with a right
ventricular TEI index >0.36 [18]) or other echocardio-
graphic abnormalities and if clinically indicated, further
diagnostic work-up was performed under supervision of
an independent expert panel. Criteria for the diagnosis
of CTEPH were mean pulmonary artery pressures
assessed by right heart catheterization exceeding 25
mmHg respectively and normal pulmonary capillary
wedge pressure in combination with an abnormal perfu-
sion scintigram and signs for distal or central CTEPH
on conventional pulmonary angiography [4].
Statistical analysis
Differences in baseline characteristics and CMR mea-
surements between patients with and without PE were
sought for using the Student’s T-test in case of normal
distribution or else the Mann-Whitney U test for pair-
wise comparisons. Variables that were normally distribu-
ted are presented as mean and standard deviation,
variables with skewed distribution as medians and inter-
quartile range. The presence of normal distribution was
tested using the Kolmogorov-Smirnov test. Finally, we
compared the CMR test results of patients with to those
without pulmonary hypertension. P-values less than 0.05
were considered significant.
Results
Study patients
To achieve our sample size goal, we followed 27 consecu-
tive patients with acute PE and 15 consecutive patients in
whom PE was ruled out. From these patients, 3 had died
during the 6 months follow-up period and 14 were
excluded because of implanted cardiac pacemaker,
unwillingness to cooperate or claustrophobia, leaving 15
patients diagnosed with and 10 patients without PE for
analysis. The demographic characteristics of the two
patient cohorts were comparable (table 1); overall mean
age was 53 ± 11 years and 14 (60%) of the patients were
of male gender. The distribution of cardiopulmonary
comorbidity was comparable as well. None of the
patients without PE had a history of venous thrombosis
or developed venous thrombosis during the 6 months fol-
low-up period. Median follow-up duration of the overall
population was 205 days (range 165-301 days), and was
not different between the two study cohorts (table 1).
The median Qanadli score of the patients with PE was
15 with a range of 2 to 26 (table 1). The systolic perfor-
mance of both the right and left ventricle of the patients
with PE was significantly impaired compared to the con-
trol patients without PE: median right ventricular ejec-
tion fraction 47 (39-53) versus 55 (52-58; p = 0.014) and
mean left ventricular ejection fraction 54.1 ± 8.2% ver-
sus 60.1 ± 3.5% (p = 0.038) for patients with and with-
out PE respectively.
Pulmonary artery flow dynamics
After six months follow up, right ventricular ejection
fraction was not statistically significant different between
patients with PE and control patients without PE (med-
ian 54.5%; interquartile range 51.8-60.4 versus 54.3%;
51.0-56.6, p = 0.57, Figure 1). In contrast, patients with
PE had statistically significant lower left ventricular ejec-
tion fraction than patients without PE (mean 54.7% ±
5.8 versus 59.5% ± 3.5, p = 0.016). The pulmonary artery
distensibility index was not different between patients
with and without PE (0.18 ± 0.18 versus 0.25 ± 0.18, p
= 0.20). Also, the studied pulmonary hemodynamic
parameters were not different between patients with and
without PE: mean velocity 14.1 ± 3.9 cm/s versus 14.0 ±
2.5 cm/s (p = 0.81), peak velocity 86.5 ± 22 cm/s versus
89.6 ± 13 cm/s (p = 0.43), and time to peak velocity 142
± 49 ms vs 161 ± 29 ms (p = 0.14; Figure 1).
CMR as potential screening tool for CTEPH
All study participants underwent echocardiography after
the CMR scan that revealed only one patient with PE
suspected of having pulmonary hypertension. The diag-
nosis of inoperable CTEPH was confirmed after right
heart catheterization and conventional angiography.
This female patient was 59 years old, was diagnosed
initially with idiopathic pulmonary embolism and
expressed symptoms of exertional dyspnea and
decreased exercise tolerance. At time of diagnosis of
CTEPH, she was classified in NYHA class III and her
Klok et al. Journal of Cardiovascular Magnetic Resonance 2011, 13:14
http://www.jcmr-online.com/content/13/1/14
Page 3 of 6mean pulmonary arterial pressure was 48 mmHg.
Results from the CMR measurements in this patient
indicated decreased systolic performance and increased
stiffness of the pulmonary artery (Figure 1). Even more,
she had the lowest right ventricular ejection fraction
(19.9%), distensibility index (0.03), mean pulmonary
artery velocity (7.11 cm/s), peak pulmonary artery velo-
city (44.6 cm/s) and time to peak velocity (97 ms) of all
study patients. Strikingly, the pulmonary artery flow
curve of the patient with CTEPH had an abnormal
shape, i.e. a steep pulmonary flow systolic notch
(Figure 2). This notch represents the increased wave
reflection in the pulmonary artery caused by a stiffened
pulmonary artery wall or obstruction of the blood flow,
and the timing of the notch distinguishes proximal from
distal obstruction of the pulmonary artery in acute PE
as well as in CTEPH [19].
Discussion
The main finding of this study is that CMR measured
pulmonary artery flow profiles of patients treated for
acute PE do not differ from that of control patients
without PE, whereas the same patients with PE had sig-
nificantly different systolic cardiac performance com-
pared to the same control patients without PE at time
of diagnosis before treatment was initiated. This obser-
vation possibly indicates normalization of the pulmonary
flow dynamics in the majority of patients after PE. One
additional finding of this study is that CMR is a poten-
tially valuable screening tool for CTEPH after PE since
measurements of the pulmonary artery flow profile in
combination with RV function might be discriminative
for pulmonary hypertension.
There is great need to develop tools for early identifi-
cation of patients in early clinical stages of CTEPH.
Only in case of successful pulmonary endarterectomy,
CTEPH is a potentially curable but otherwise lethal dis-
ease [2]. Early identification of CTEPH is likely to
i m p r o v et h ed i s e a s es p e c i f i cp r o g n o s i ss i n c ee v e nw h e n
pulmonary endarterectomy is achievable, pulmonary
artery pressure and resistance as well as functional sta-
tus of the patients remain important prognostic factors
[20]. Because the incidence of CTEPH is reported to be
as high as 3.8% or even 8.8% [21,22], screening pro-
grams for CTEPH might be considered in the clinical
follow-up of patients with acute PE. Such screening pro-
grams should employ tools that are non-invasive, widely
available and applicable, and importantly, can distin-
guish patients who are in early stages of CTEPH from
those who are not at risk of developing this condition.
The results of this study support the potential role of
CMR as early screening tool for CTEPH after acute PE
for two reasons. CMR is a widely available and non
invasive imaging modality. Furthermore, since the
hemodynamics of the pulmonary artery are restored
after 6 months of treatment for acute PE, and patients
with CTEPH have a clearly different flow profile [6-10],
CMR may be able to distinguish patients with clinical
relevant pulmonary hypertension from those who are
fully recovered, although the design and the number of
cases with pulmonary hypertension in our study does
not allow to access the value of CMR as a screening
tool.
By design of our study, we were not able to evaluate
the ability of CMR to identify patients with very early
stages of disease, who are likely to develop symptomatic
CTEPH over time. Nonetheless, previous reports have
suggested that pulmonary artery distensibility is
decreased during acute PE, but recovers over time after
treatment [9]. Furthermore, pulmonary artery distensi-
bility increases early in the course of pulmonary hyper-
tension, i.e. even when pulmonary hypertension is
detectable only with exercise and before overt pressure
elevations occur at rest [10]. These reports as our results
underline the potential of CMR as screening tool for
CTEPH.
The strengths of our study include the prospective
design and the inclusion of consecutive patients. We
Table 1 Baseline characteristics of study patients
PE patients
(n = 15)
Patients without PE
(n = 10)
Age ([years] mean, ± SD) 53 ± 10 52 ± 13 NS
Female gender (n, %) 7 (47) 7 (70) NS
History of venous thrombosis (n, %) 6 (40) 0 (0) NS
COPD (n, %) 3 (20) 2 (20) NS
Pre-existent left heart failure (n, %) 1 (6.7) 0 (0) NS
Qanadli score (median, IC range) 15 (2-26) NA
Right ventricular ejection fraction by CT (%, median, IC range) 47 (39-53) 55 (52-58) p = 0.014
Left ventricular ejection fraction by CT (%, median, IC range) 54 (31-63) 60 (55-65) p = 0.038
Follow-up duration (days; mean, ± SD) 226 ± 42 202 ± 36 NS
PE = pulmonary embolism, n = number, SD = standard deviation, NA = not applicable, IC = interquartile.
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previous studies indicate excellent reproducibility for the
used methods [19]. In addition to accurate measure-
ments of cardiac volumes, CMR is widely accepted as
the reference standard for evaluating the pulmonary
artery flow. Study limitations are the limited sample size
and only six months follow up without pulmonary flow
measurements at the time of the acute event, which
would have allowed evaluating the usefulness of CMR as
early screening tool for CTEPH and possible changes of
pulmonary flow profiles over time. Future studies should
include larger patient cohorts and longer follow-up per-
iod. Furthermore, focus of these studies should not only
be to detect patients with overt CTEPH but also on
establishing relevant threshold values for pulmonary
hemodynamic parameters to indentify patients who are
at risk of developing clinical relevant CTEPH in the fol-
lowing years. These patients then could be subjected to
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Figure 1 Distribution of right and left ventricular ejection fraction, distensibility index and flow characteristics of the pulmonary
artery in the study population. The patient with CTEPH is indicated with the open box. Medians (right ventricular ejection fraction) and
means (all other parameters) are indicated. *p < 0.05.
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pulmonary hypertension centers, to facilitate early diag-
nosis and treatment, leading to improved prognosis.
In summary, right ventricular systolic performance
and flow curve profiles of patients with PE after 6
months of treatment are generally comparable to those
in patients in whom PE was suspected but ruled out.
Furthermore, CMR may be helpful to identify patients
with CTEPH. Further studies are needed to evaluate the
potential role of CMR as screening tool for CTEPH
after acute PE.
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Figure 2 Pulmonary artery flow curve of the patient that was
diagnosed with CTEPH and that of a healthy control without
PE. Note the pulmonary flow systolic notch (arrow) and also
diastolic forward flow as marker of restrictive physiology
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